COMPLEMENT 3 GLOMERULONEPHRITIS

Clinical trials for COMPLEMENT 3 GLOMERULONEPHRITIS explained in plain language.

Never miss a new study

Get alerted when new COMPLEMENT 3 GLOMERULONEPHRITIS trials appear

Sign up with your email to follow new studies for COMPLEMENT 3 GLOMERULONEPHRITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Completed 1

New hope for rare kidney disease patients through early access program

Disease control APPROVED_FOR_MARKETING

This program provides early access to an investigational drug called pegcetacoplan for patients with rare kidney diseases C3G or IC-MPGN. It's for people aged 12+ who haven't responded well to other treatments and have active kidney disease. Participants must be able to self-admi…

Matched conditions: COMPLEMENT 3 GLOMERULONEPHRITIS

Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 23, 2026 15:17 UTC

COMPLEMENT 3 GLOMERULONEPHRITIS

Get alerted when new COMPLEMENT 3 GLOMERULONEPHRITIS trials appear

New hope for rare kidney disease patients through early access program